VRCA
Verrica Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.46
+5.02%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.39
From 52W high−62.03%
Volume30374.00
Market cap$59.35M
P/E (TTM)—
P/S (TTM)2.0x
Div yield—
Key dataNov 4, 2026
Open
$3.39
From 52W high
−62.03%
Volume
30374.00
Market cap
$59.35M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.9x
P/E (TTM)
—
RSI (14)
39.3
MomentumView details →
1D Return
+5.02%
YTD Return
−58.84%
SummaryUpdated Jun 1, 2026
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) is a dermatology-focused biotechnology company founded in 2013 and headquartered in West Chester, Pennsylvania. The company went public in June 2018 and specializes in developing and commercializing treatments for various skin diseases. Verrica's primary focus is on cantharidin-based therapies, with its lead product YCANTH being the first and only FDA-approved treatment for molluscum contagiosum, a common viral skin infection primarily affecting children. The company has evolved from a pure development-stage biotech to a commercial-stage pharmaceutical company with an expanding product pipeline targeting multiple dermatological conditions.
Similar companies
Latest newsMore news →
Verrica Pharmaceuticals achieved the revenue, growth and operational milestones that increased the maximum commitment under its credit facility by $15.0 million, making the full $27.5 million available.14d agoVerrica Pharmaceuticals announced it will present data on YCANTH and VP-315 at two upcoming dermatology conferences.56d agoVerrica Pharmaceuticals completed enrollment in the first pivotal Phase 3 trial (COVE-2) evaluating YCANTH for the treatment of common warts, with topline data expected in Q1 2027.70d ago